Nitric Oxide and Cardiovascular Risk Factors

Tentolouris C. , Tousoulis D. , Goumas G. , Stefanadis C. , Davies G. , Toutouzas P. L-Arginine in coronary atherosclerosis. Int J Cardiol 2000; 75: 123–8.

Scarabelli T.M. , Stephanou A. , Pasini E. Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ichaemia-riperfusion. Circ Res 2002 5; 90: 745–78.

Zeiher A.M. , Drexler H. , Saurbier B. , Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652–62.

Brandes R.P. , Fleming I. , Busse R. Endothelial aging. Cardiovasc Res 2005; 66: 286–94.

Orlandi A. , Bochaton-Piallat M.L. , Gabbiani G. , Spagnoli L.G. Aging, smooth muscle cells and vascular pathobiology: implications for atherosclerosis. Atherosclerosis 2006; 188: 221–30.

Yildiz O. Vascular smooth muscle and endothelial functions in aging. Ann N Y Acad Sci 2007; 1100: 353–60.

Griendling K.K. , Minieri C.A. , Ollerenshaw J.D. , Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–8.

Taddei S. , Virdis A. , Mattei P. , Natali A. , Ferrannini E. , Salvetti A. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation 1995; 92: 2911–8.

Armas-Padilla M.C. , Armas-Hernandez M.J. , Sosa-Canache B. Nitric oxide and malondialdehyde in human hypertension. Am J Ther 2007; 14: 172–6.

Kuzkaya N. , Weismann N. , Harrison D.G. , Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase. J Biol Chem 2003; 278: 22546–54.

Drab M. , Verkade P. , Elger M. Loss of caveolae, vascular dysfunction and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293: 2449–52.

De Vriese A.S. , Verbeuren T.J. , van de Voorde J. , Lameire N.H. , Vanhoutte P.M. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963–74.

Baron A.D. , Steinberg H.O. , Chaker H. , Leaming R. , Johnson A. , Brechtel G. Insulin- mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995; 96: 786–92.

Freeman D.J. , Norrie J. , Sattar N. Pravastatin and the development of the diabetes mellitus: evidence for a protective treatment effect in the West Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.

Yusuf S. , Sleight P. , Pogue J. , Bosch J. , Davies R. , Dagenais G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.

Kaufmann P.A. , Gnecchi-Ruscone T , Camici P.G. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000; 102: 1233–8.

Taddei S. , Ghiadoni L. , Salvetti G. , Virdis A. , Salvetti A. Obesity and endothelial dysfunction. G Ital Cardiol 2006; 7: 715–23.

Stanger O. , Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged endothelium. Clin Chem Lab Med 2003; 41: 1444–54.

Ungvari Z. , Csiszar A. , Edwards J.G. Increased super-oxide production in coronary arteries in hyperhomocysteinemia. Role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2003; 23: 418–23.

Böger R.H. , Lentz S.R. , Bode-Böger S.M. , Knapp H.R. , Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inemia in humans. Clin Sci (Lond) 2001; 100: 161–7.

Stühlinger M.C. , Tsao P.S. , Her J.H. , Kimoto M. , Balint R.F. , Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetrical dimethylarginine. Circulation 2001; 104: 2569–75.

Refsum H. , Ueland P.M. , Nygard O. , Vollset S.E. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31–62.

Leiper J. , Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43: 542–8.

Boger R.H. , Bode-Boger S.M. , Szuba A. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–7.

Surdacki A. , Nowichi M. , Sandmann J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–8.

Abbasi F. , Asagmi T. , Cooke J.P. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201–3.

Zoccali C. , Bode-Boger S.M. , Mallamaci F. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–7.

Valkonen V.P. , Paiva H. , Salonen J.T. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127–8.

Lu T.M. , Ding Y.A. , Lin S.J. , Lee W.S. , Tai H.C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003; 24: 1912–9.

Krempl T.K. , Maas R. , Sydow K. , Meinertz T. , Boger R.H. , Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26: 1846–51.

Zhang W.Z. , Venardos K. , Chin-Dusting J. , Kaye D.M. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 2006; 48: 278–85.

Michaud S.E. , Dussault S. , Groleau J. , Haddad P. , Rivard A. Cigarette smoke exposure impairs VEGF-induced endothelial cell migration: role of NO and reactive oxygen species. J Mol Cell Cardiol 2006; 41: 275–84.

Davidson S.M. , Duchen M.R. Endothelial mitochondria: contributing to vascular function and disease. Circ Res 2007; 100: 1128–41.

Belge C. , Massion P.B. , Pelat M. , Balligand J.L. Nitric oxide and the heart: update on new paradigms. Ann N Y Acad Sci 2005; 1047: 173–82.

Paulus W.J. , Bronzwaer J.G. Myocardial contractile effects of nitric oxide. Heart Fail Rev 2002; 7: 371–83.

Gealekman O. , Abbasi Z. , Rubinstein I. , Winaver J. , Binah O. Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. Circulation 2002; 105: 236–43.

Saito T. , Hu F. , Tayara L. , Fahas L. , Shennib H. , Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 2002; 283: H339–45.

Cotter G. , Kaluski E. , Blatt A. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000; 101: 1358–61.

Ignarro L.J. , Balestrieri M.L. , Napoli C. Nutrition, physical activity, and cardiovascular disease: an update. Cardiovasc Res 2007; 73: 326–40.

Calder P.C. n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 2004; 107: 1–11.

Kabat A. , Dhein S. L-arginine supplementation prevents the development of endothelial dysfunction in hyperglycaemia pharmacology. Pharmacology 2006; 76: 185–91.

Lerman A. , Burnett J.C. , Higano S.T. L-Arginine supplementation prevents the development of endothelial dysfunction in hyperglycaemia. Pharmacology 2006; 76: 185–95.

Kinlay S. , Behrendt D. , Fang J.C. Long term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004; 43: 629–34.

Wilmink H.W. , Stroes E.S. , Erkelens W.D. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 2000; 20: 185–8.

Ghiadoni L. , Magagna A. , Versari D. , Kardasz I. , Huang Y. , Taddei S. , Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–6.

Dagenais J.R. , Yusuf S. , Bourassa M.G. Effects of ramipril on coronary events in high risk persons: result of the heart outcomes prevention evaluation study. Circulation 2001; 104: 522–6.

Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383–9.

Tzemos N. , Lim P.O. , MacDonald T.M. Nebivolol Reverses endothelial disfunction in essential hypertension. Circulation 2001; 104: 511–4.

Juonala M. , Viikari J.S. , Laitinen T. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 2004; 110: 2918–23.